期刊文献+

低氧诱导因子-1ɑ、血管内皮生长因子及其受体在胰腺癌中的表达和预后 被引量:4

Expression of hypoxia-inducible factor-1ɑ, vascular endothelial growth factor and its receptors in pancreatic cancer and prognosis of patients
下载PDF
导出
摘要 目的探讨胰腺癌组织中低氧诱导因子-1ɑ(HIF-1ɑ)、血管内皮生长因子(VEGF)及VEGF受体1(VEGFR1)、受体2(VEGFR2)对胰腺癌微血管密度(MVD)的影响,以及这些蛋白的表达与胰腺癌根治性手术后患者生存期的关系。方法收集2008年1月—2012年5月在上海交通大学医学院附属仁济医院普外科行胰十二指肠切除术的50例胰腺癌患者的胰腺癌组织病理标本,并随机取其中15例患者的胰腺阴性切缘组织作为对照。采用免疫组织化学法检测胰腺癌组织、阴性切缘组织中HIF-1ɑ、VEGF、VEGFR1、VEGFR2的表达水平。以CD34单克隆抗体显示肿瘤微血管内皮细胞,计算肿瘤内MVD。结果共随访45例,随访率为90%。胰腺癌组织中HIF-1α、VEGF、VEGFR1、VEGFR2阳性率分别为82.0%、84.0%、80.0%和84.0%,均显著高于阴性切缘组织的46.7%、26.7%、0、13.3%(P值均<0.05)。胰腺癌组织中,HIF-1α与VEGF(r=0.564)、VEGFR1(r=0.301)、VEGFR2(r=0.310)、MVD(r=0.443)呈正相关(P值均<0.05),VEGF与VEGFR1(r=0.383)、VEGFR2(r=0.342)呈正相关(P值均<0.05),VEGFR1与VEGFR2呈正相关(r=0.851,P<0.05)。胰腺癌组织中,VEGF(r=0.836)、VEGFR1(r=0.339)、VEGFR2(r=0.284)与肿瘤MVD均呈正相关(P值均<0.05)。结论胰腺癌组织中HIF-1α影响肿瘤分化,能促进VEGF、VEGFR1、VEGFR2表达,诱导肿瘤新生血管形成,增加MVD,促进肿瘤生长,影响患者术后的生存期。 Objective To explore the effect of the expression of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR2 on microvascular density (MVD) in pancreatic cancer, and to analyze the correlation between the expression of these proteins and the prognosis of patients with radical surgery. Methods Fifty paraffin-embedded specimens of pancreatic cancer were collected from the patients who underwent radical pancreatoduodenectomy between January 2008 and May 2012. Fifteen specimens of microscopically negative margin tissue were collected from these patients as control. The expression of HIF-1α, VEGF, VEGFR1 and VEGFR2 were detected by immunohistochemistry. MVD was determined by anti-CD34 monoclonal antibody. Results Totally 45 patients were followed up and the follow-up rate was 90%. The expression of HIF-1α, VEGF, VEGFR1 and VEGFR2 in tumor specimens was 82.0%, 84.0%, 80.0% and 84.0%, respectively, which was significantly higher than the control (P〈0.05). MVD in tumor specimens was also significantly higher than the control (P〈0.01). In the tumor specimens, the expression of HIF--1α was positively correlated with VEGF, VEGFR1, VEGFR2 and MVD (r = 0. 564, 0.301, 0.310, and 0. 443, P〈0.05) VEGF was positively correlated with VEGFR1 and VEGFR2 (r = 0. 383 and 0. 342, P〈0. 05) MVD was positively correlated with VEGF, VEGFR1 and VEGFR2 (r = 0. 836, 0.339, and 0. 284, P〈0. 05). Conclusion HIF-1α may impact the differentiation of pancreatic cancer and activate the expression of VEGF, VEGFR1 and VEGFR2, which induce the neovascularization and the increased MVD and cause poor prognosis.
出处 《上海医学》 CAS CSCD 北大核心 2012年第11期923-926,I0001,共5页 Shanghai Medical Journal
关键词 胰腺癌 低氧诱导因子-1ɑ 血管内皮生长因子 血管内皮生长因子受体 Pancreatic cancer Hypoxia-inducible factor-1α Vascular endothelial growth factor Vascularendothelial growth factor receptors
  • 相关文献

参考文献17

  • 1ZHONG H,DE MARZO A M,LAUGHNER E. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases[J].Cancer Research,1999,(22):5830-5835.
  • 2SUN H C,QIU Z J,LIU J. Expression of hypoxia inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis[J].International Journal of Oncology,2007,(06):1359-1367.
  • 3COUVELARD A,O'TOOLE D,LEEK R. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas[J].Histopathology,2005,(06):668-676.
  • 4KITADA T,SEKI S,SAKAGUCHI H. Clinicopathological significance of hypoxia-inducible factor1alpha expression in human pancreatic carcinoma[J].Histopathology,2003,(06):550-555.
  • 5B(U)CHLER P,REBER H A,B(U)CHLER M. Hypoxiainducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer[J].Pancreas,2003,(01):56-64.
  • 6CAMP E R,YANG A,LIU W. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer[J].Clinical Cancer Research,2006,(08):2628-2633.
  • 7KARADEMIR S,S(O)KMEN S,TERZI C. Tumor angiogenesis as a prognostic predictor in pancreatic cancer[J].Journal of Hepato-Biliary-Pancreatic Surgery,2000,(05):489-495.doi:10.1007/s005340070020.
  • 8FERRARA N. Vascular endothelial growth factor:basic science and clinical progress[J].Endocrine Reviews,2004,(04):581-611.doi:10.1210/er.2003-0027.
  • 9IKEDA N,ADACHI M,TAKI T. Prognostic significance of angiogenesis in human pancreatic cancer[J].British Journal of Cancer,1999,(9-10):1553-1563.
  • 10KARADEMIR S,S(O)KMEN S,TERZI C. Tumor angiogenesis as a prognostic predictor in pancreatic cancer[J].Journal of Hepato-Biliary-Pancreatic Surgery,2000,(05):489-495.doi:10.1007/s005340070020.

同被引文献39

  • 1World Health Organization. Section of cancer information [ EB/ OL]. ( 2012-04-03 ) [ 2015-01-02 ]. http ://globocan.iarc. fr/fact- sheet.asp#MORTALITY 1.
  • 2Folkman J. Tumor angiogenesis : therapeutic implications [ J ]. N Engl J Med, 1971, 285(21) :1182-1186.
  • 3Qin SK, Bai Y, Sun Y, et al. Phase III study of oxaliplatin plus 5-fluomuraciL/leucoverin( FOLFOX 4) versus doxorubicin as pal- liative systemic chemotherapy in advanced HCC in Asian pts[ J]. J Clin Oncol, 2010, 28(15(Suppl) ) :4008.
  • 4Yu Y, Zhang CL, Liu LJ, et al. Hepatic arterial administration of ginsenoside Rg3 and transeatheter arterial embolization for the treatment of VX2 liver carcinomas[ J]. Exp Ther Med, 2013, 5 (3) :761-766.
  • 5Strebel BM, Dufour JF. Combined approach to hepatocellular ear- cinoma: a new treatment concept for nonresectable disease [ J ]. Expert Rev Anticancer Ther, 2008, 8 ( 11 ) : 1743-1749.
  • 6Gershtein ES,Dubova EA, Shchegolev AI, et al. Vascular endo- thelial growth factor and its type 2 receptor in hepatocelluar carci- noma[J]. Bull Exp Biol Med, 2010, 149(6) :749-752.
  • 7Joanna O, Andrzej D. Effective therapeutic management of hepa- tocellular carcinoma on the basis of a clinical case[ J]. Wspolcz- esna Onkol, 2012, 16(2) :60-63.
  • 8Dhar PK, Naora H, Yamanoi A, et al. Requisite role of VEGF receptors in angiogensis ofhepatocellular carcinoma:a comparison with angiopoietin/Tie pathway [ J ]. Anticancer Res, 2012, 22 (1A) :379-386.
  • 9Liu L, Cao Y, Chen C, et al. Sorafenib bloeks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [ J ]. Cancer Res, 2006, 66 (24) : 11851 - 11858.
  • 10周爱萍,何志嵩,于世英,张沂平,杜春霞,孙永昆,石远凯,王金万,那彦群,孙燕.索拉非尼治疗转移性肾癌的临床研究[J].中华泌尿外科杂志,2009,30(1):10-14. 被引量:54

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部